Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells

PARP inhibitors have been proposed as a potential targeted therapy for patients with triple-negative (ER-, PR-, HER2-negative) breast cancers. However, it is as yet unclear as to whether single agent or combination therapy using PARP inhibitors would be most beneficial. To better understand the mech...

Descripción completa

Detalles Bibliográficos
Autores principales: Bajrami, Ilirjana, Kigozi, Asha, Van Weverwijk, Antoinette, Brough, Rachel, Frankum, Jessica, Lord, Christopher J, Ashworth, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: WILEY-VCH Verlag 2012
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491838/
https://www.ncbi.nlm.nih.gov/pubmed/22933245
http://dx.doi.org/10.1002/emmm.201201250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491838/
https://www.ncbi.nlm.nih.gov/pubmed/22933245
http://dx.doi.org/10.1002/emmm.201201250

Ejemplares similares